Literature DB >> 22868174

Human disease modeling with induced pluripotent stem cells.

Alan Trounson1, Kelly A Shepard, Natalie D DeWitt.   

Abstract

In the past few years, cellular programming, whereby virtually all human cell types, including those deep within the brain or internal organs, can potentially be produced and propagated indefinitely in culture, has opened the door to a new type of disease modeling. Importantly, many diseases or disease predispositions have genetic components that vary from person to person. Now cells from individuals can be readily reprogrammed to form pluripotent cells, and then directed to differentiate into the lineage and the cell type in which the disease manifests. Those cells will contain the genetic contribution of the donor, providing an excellent model to delve into human disease at the level of individuals and their genomic variants. To date, over fifty such disease models have been reported, and while the field is young and hurdles remain, these tools promise to inform scientists about the cause and cellular-molecular mechanisms involved in pathology, unravel the role of environmental versus hereditary factors driving disease, and provide an unprecedented tool for screening therapeutic agents that might slow or halt disease progression.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22868174     DOI: 10.1016/j.gde.2012.07.004

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  30 in total

1.  New markers for tracking endoderm induction and hepatocyte differentiation from human pluripotent stem cells.

Authors:  Audrey Holtzinger; Philip R Streeter; Farida Sarangi; Scott Hillborn; Maryam Niapour; Shinichiro Ogawa; Gordon Keller
Journal:  Development       Date:  2015-10-22       Impact factor: 6.868

Review 2.  Proceedings: consideration of genetics in the design of induced pluripotent stem cell-based models of complex disease.

Authors:  Uta Grieshammer; Kelly A Shepard
Journal:  Stem Cells Transl Med       Date:  2014-11       Impact factor: 6.940

Review 3.  Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming.

Authors:  I K Rony; A Baten; J A Bloomfield; M E Islam; M M Billah; K D Islam
Journal:  Cell Prolif       Date:  2015-01-29       Impact factor: 6.831

4.  Induced pluripotent stem cells, form in vitro tissue engineering to in vivo allogeneic transplantation.

Authors:  Yi-Chen Li; Kai Zhu; Tai-Horng Young
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

5.  A global assessment of stem cell engineering.

Authors:  Jeanne F Loring; Todd C McDevitt; Sean P Palecek; David V Schaffer; Peter W Zandstra; Robert M Nerem
Journal:  Tissue Eng Part A       Date:  2014-02-28       Impact factor: 3.845

Review 6.  Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery.

Authors:  Katherine A Campbell; Andre Terzic; Timothy J Nelson
Journal:  Regen Med       Date:  2015-10-06       Impact factor: 3.806

Review 7.  Great expectations: autism spectrum disorder and induced pluripotent stem cell technologies.

Authors:  Emily Yang Liu; Christopher Thomas Scott
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

Review 8.  Epigenetics of reprogramming to induced pluripotency.

Authors:  Bernadett Papp; Kathrin Plath
Journal:  Cell       Date:  2013-03-14       Impact factor: 41.582

9.  Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.

Authors:  Barbara Calamini; Donald C Lo; Linda S Kaltenbach
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

10.  Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells.

Authors:  Zhaohui Ye; Cyndi F Liu; Lucie Lanikova; Sarah N Dowey; Chaoxia He; Xiaosong Huang; Robert A Brodsky; Jerry L Spivak; Josef T Prchal; Linzhao Cheng
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.